B.Sc. [Microbiology] (University of Alberta), Ph.D. [Microbiology] (University of British Columbia)
Professor, Department of Pathology and Laboratory Medicine, University of British Columbia
Research InterestsAging; lipid metabolism; Neurodegeneration; neuroscience; pathology
Dr. Wellington’s major research interests are on both genetic and environmental factors that modulate risk for Alzheimer Disease (AD), the most common dementia. An increasingly recognized environment risk factor for dementia includes a history of traumatic brain injury (TBI). Current projects include understanding how injury severity, number of injuries, and age at injury all affect dementia risk, and understanding how the neuropathology and clinical presentation of TBI-related syndromes overlap with classical dementias. Over two million TBIs occur annually in North America, with rapidly increasing public concern over the long-term effects of concussion on brain health during development and aging. Existing animal models of TBI, however, fail to replicate the mechanics of most real-life human TBIs, which are caused by sharp, angular and/or linear accelerations or decelerations of a freely moving intact head.
Working with biomechanical engineers at ICORD, Dr. Wellington and her colleagues have developed a transformative new model of rodent closed head TBI, called CHIMERA (Closed Head Injury Model of Engineered Rotational Acceleration) that was specifically designed to overcome the caveats that limit the translational relevance of existing TBI models. CHIMERA’s innovation lies in its ability to generate, in a biomechanically controlled and reproducible manner, a wide range of TBI severity with completely free head movement, where head motion analyses are integrated with behavioral and neuropathological outcomes.
Current Lab Members
|Ph.D. Students||Postdoctoral Fellows||Research Staff|
|Wai Hang Cheng (Tom)||Kris Martens||Anna Wilkinson|
|Emily Button||Jerome Robert||Iva Kulic|
|Guilaine||Jianjia Fan||Jeniffer Chan|
|Asma Bashir||Qingchun Mu|
|2016||Iva Kulic||Weston Brain Institute Rapid Response Grant (Weston Brain Institute)|
|2016||Jerome Robert||Weston Brain Institute Rapid Response Grant (Weston Brain Institute)|
|2016||Emily Button||Top 3% of CIHR Doctoral Award (CIHR)|
|2016||Asma Bashir||CIHR Masters Scholarship (CIHR)|
- Gibbs, E et al.. 2019. A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease.. Sci Rep. doi: 10.1038/s41598-019-46306-5.
- Button, EB et al.. 2019. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.. Alzheimers Res Ther. doi: 10.1186/s13195-019-0497-9.
- Button, EB et al.. 2019. HDL from an Alzheimer's disease perspective.. Curr. Opin. Lipidol. doi: 10.1097/MOL.0000000000000604.
- Vonder Haar, C et al.. 2019. Repetitive closed-head impact model of engineered rotational acceleration (CHIMERA) injury in rats increases impulsivity, decreases dopaminergic innervation in the olfactory tubercle and generates white matter inflammation, tau phosphorylation and degeneration.. Exp. Neurol. doi: 10.1016/j.expneurol.2019.02.012.
- Button, EB et al.. 2019. Vasoprotective Functions of High-Density Lipoproteins Relevant to Alzheimer's Disease Are Partially Conserved in Apolipoprotein B-Depleted Plasma.. Int J Mol Sci. doi: 10.3390/ijms20030462.